Topics

GTHX Jumps On Regulatory Update On Trilaciclib In Small Cell Lung Cancer

22:21 EDT 29 Apr 2019 | RTTNews

Shares of G1 Therapeutics Inc. (GTHX) rose more than 19% in after-hours on Monday, following positive regulatory update on Trilaciclib, an intravenous CDK4/6 inhibitor in development, to reduce *myelosuppression and enhance immune system function during chemotherapy.

Original Article: GTHX Jumps On Regulatory Update On Trilaciclib In Small Cell Lung Cancer

NEXT ARTICLE

More From BioPortfolio on "GTHX Jumps On Regulatory Update On Trilaciclib In Small Cell Lung Cancer"

Quick Search